Gynecologic Cancers
Oncology Nursing News’ Top ASCO Picks
June 28, 2022
Article
We rounded up 5 stories from the 2022 ASCO Annual Meeting that are of most value to oncology nurses.
Experts Make the Case for Buprenorphine Use in Cancer-Related Pain Management
June 28, 2022
Article
Mary Lynn McPherson, PharmD, BCPS, FAAHPM, and Amy A. Case, MD, FAAHPM, argue that buprenorphine should play a larger role in cancer-related pain management because of its unique pharmacology and consequent safety profile.
Oral Minoxidil Demonstrates Efficacy in Treating Later Stage Alopecia in Cancer Survivors
June 27, 2022
Article
Results of a single-center study presented at the 2022 ASCO Annual Meeting showed that oral minoxidil may be effective in treating late alopecia. Moving forward, these efforts in survivorship care will need to be expanded to less resourced areas, experts said.
FDA Grants Accelerated Approval to Dabrafenib Plus Trametinib for BRAF V600E–Mutated Solid Tumors
June 23, 2022
Article
The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.
Roxadustat Increases Hemoglobin Counts in Patients With Chemotherapy-Induced Anemia
June 21, 2022
Article
Phase 2 findings found that patients with chemotherapy-induced anemia experienced increases in hemoglobin following treatment with roxadustat.
Aliènne Salleroli on Starting the DEI Conversation in Oncology Nursing
June 20, 2022
Video
Aliènne Salleroli, MS, BSN, RN, OCN, underscores the importance of open dialogue surrounding diversity, equity, and inclusion in oncology leadership.
Prescribing 20 mg of Mozart for Chemotherapy-Induced Nausea
June 20, 2022
Article
A Michigan State University investigator is preparing to expand on an encouraging pilot study that used a music-listening intervention to influence chemotherapy-induced nausea.
Patients Receiving PD-1/PD-L1 Inhibitor Therapy More Frequently Experience Secondary Adrenal Insufficiency
June 17, 2022
Article
A study analyzing the long-term adrenal insufficiency outcomes of patients receiving immune checkpoint inhibition therapy found that secondary insufficiency was more common than primary in this patient population.
Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer
June 14, 2022
Article
A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.
Frontline Bevacizumab Prolongs PFS, OS in Ovarian Clear Cell Carcinoma
June 11, 2022
Article
Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.